drugset / Trial / NCT05330273
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz
NaSequentialOpen-labelTreatment
Summary
This study assessed the effect of multiple doses of a moderate inducer of cytochrome P450 (CYP) 3A4 (efavirenz) on the pharmacokinetics (PK) of ganaplacide and lumefantrine combination. Results from this study will provide guidance on prescribing ganaplacide and lumefantrine combination when co-administered with moderate inducers of CYP3A4.
Timeline
- Start
- 2022-04-28
- Primary completion
- 2022-11-22
- Completion
- 2022-11-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efavirenz | Other / unclassified | 600 mg | Oral |
| Subject | Ganaplacide | Small molecule | 400 mg | Oral |
| Subject | lumefantrine | Small molecule | 480 mg | Oral |